Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has ...

On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the ...

Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension. The agency recommended the ...

While the Dow Jones Industrial Average has reached all-time highs recently, one of its newest members, Merck, traded briefly Thursday morning at a 52-week low.

Pharmaceuticals firm Merck reported a solid third quarter on Thursday, with revenue up 4% year-over-year to $16.7bn, driven by robust sales of its cancer drug Keytruda, although muted demand for the ...

Merck MRK reported third-quarter 2024 adjusted ... in certain international markets hurt the drug's sales. New PAH drug Winrevair, which received FDA approval in March, generated sales of $149 ...

The newly approved Winrevair (sotatercept) for adults with pulmonary arterial hypertension generated sales of $149 million. Goldman reiterates the Buy rating for Merck ... that the drug is ...

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

and a slightly underwhelming post launch revenue figure of $70m for pulmonary arterial hypertension drug Winrevair, which Merck has suggested could be a ~$6bn peak revenue drug. Winrevair has ...

The Food and Drug Administration ... a medicine for pulmonary arterial hypertension, stemmed from the acquisition of Acceleron Pharma. Merck also has several collaboration agreements with smaller ...